The approval makes AQVESME the only FDA-approved therapy for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia
Masitinib targets mast cells, which play a critical role in severe forms of SCD and its complications, including vaso-occlusive crises, acute chest syndrome, and pain
Full approval will depend on verification of clinical benefit in a confirmatory trial
Efdoralprin alfa, a recombinant human alpha-1 antitrypsin (AAT)-Fc fusion protein, showed superior efficacy to standard plasma-derived therapy in adults with AATD
The receipt of this permission paves way for the marketing of Datopotamab Deruxtecan powder for concentrate for solution for infusion 100 mg (r-DNA origin) in India
Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusion
Golcadomide, a CELMoD agent, continued to deliver deep and durable responses in aggressive B-cell and follicular lymphomas
It's a development that marks a potential breakthrough for people living with the rare and debilitating disease Duchenne muscular dystrophy (DMD)
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
DUPLEX’s two-compartment, PVC- and DEHP-free design keeps medication and diluent separate until activation
Subscribe To Our Newsletter & Stay Updated
